Dubbed “ Ozempic face ,” a term coined by celebrity dermatologist Dr. Paul Jarrod Frank, the gaunt appearance is a growing ...

Learn how GLP-1 weight loss medications like Wegovy work in the body and whether over-the-counter GLP-1 supplements are as ...

Viking currently boasts a market valuation of $8.1 billion. For an unprofitable biotech company without approved products, ...

During a protest outside the Kaiser Permanente San Francisco Medical Center this week, union nurses rallied against: True or ...

There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, ...

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

Anktiva, an IL-15 agonist, also shows promise for other malignancies, including non-small-cell lung cancer, and even for HIV.

Gilead Sciences Inc. is aiming to capitalize on the early August 2022 buyout of privately held U.K. biotech Mirobio Ltd. with ...

While still early stage, the company has had positive Phase 2 data on a GLP-1/GIP agonist injectable candidate potentially ...

A first-in-class interleukin (IL)-15 receptor agonist, the drug is specifically approved in combination with BCG for adults ...

The U.S. is set to see a surge in obesity drug introductions over the next five years. Here’s a rundown of the potential ...

Medications like Ozempic and Mounjaro have revolutionized the treatment of Type 2 diabetes and obesity — and they have grown ...